Rockwell Medical (NASDAQ:RMTI) announced its quarterly earnings results on Tuesday. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01), MarketWatch Earnings reports. Rockwell Medical had a negative return on equity of 117.67% and a negative net margin of 47.23%.
Shares of RMTI stock traded down $0.01 on Thursday, hitting $1.16. 18,710 shares of the stock were exchanged, compared to its average volume of 2,158,408. The company has a current ratio of 6.13, a quick ratio of 5.83 and a debt-to-equity ratio of 0.50. The firm has a market capitalization of $108.08 million, a P/E ratio of -2.63 and a beta of 1.11. The business has a 50-day moving average of $1.42 and a 200 day moving average of $1.18. Rockwell Medical has a fifty-two week low of $0.83 and a fifty-two week high of $2.62.
Several equities research analysts have issued reports on the company. HC Wainwright lowered their price target on Rockwell Medical from $9.00 to $5.50 and set a “buy” rating for the company in a report on Monday, February 8th. Zacks Investment Research downgraded Rockwell Medical from a “hold” rating to a “strong sell” rating in a report on Friday, February 12th.
Rockwell Medical, Inc operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis. The company offers Triferic, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores; and Calcitriol, an active vitamin D injection for the management of hypocalcemia in patients undergoing chronic hemodialysis.
Featured Story: NASDAQ
Receive News & Ratings for Rockwell Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical and related companies with MarketBeat.com's FREE daily email newsletter.